[go: up one dir, main page]

AR123158A1 - Proteínas de fusión del ligando para flt3 y métodos de uso - Google Patents

Proteínas de fusión del ligando para flt3 y métodos de uso

Info

Publication number
AR123158A1
AR123158A1 ARP210102188A ARP210102188A AR123158A1 AR 123158 A1 AR123158 A1 AR 123158A1 AR P210102188 A ARP210102188 A AR P210102188A AR P210102188 A ARP210102188 A AR P210102188A AR 123158 A1 AR123158 A1 AR 123158A1
Authority
AR
Argentina
Prior art keywords
protein
seq
effector
flt3
nucleic acid
Prior art date
Application number
ARP210102188A
Other languages
English (en)
Inventor
Yichin Liu
Christine Carine Moussion
Travis William Bainbridge
Iraj Hosseini
Gregory Alan Lazar
Sivan Cohen
Christopher Charles Kemball
Jill M Schartner
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR123158A1 publication Critical patent/AR123158A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una proteína de fusión Fc que comprende una proteína Fc no efectora que comprende un proteína de ligando para Flt3 (Flt3L) y la proteína Fc no efectora, en la que la proteína Fc no efectora es al menos 95%, 96%, 97%, 98% o 99% idéntica a los residuos de SEQ ID Nº 13, y en la que los residuos 13 - 17 de SEQ ID Nº 13 comprenden la secuencia de aminoácidos PVAGP (SEQ ID Nº 20) y el residuo 76 de SEQ ID Nº 13 es una glicina. Reivindicación 10: Un ácido nucleico aislado que codifica la proteína de fusión Fc de una cualquiera de las reivindicaciones 1 a 9. Reivindicación 11: El ácido nucleico aislado de acuerdo con la reivindicación 10, en la que el ácido nucleico aislado codifica además una secuencia de señal en el extremo N terminal de la proteína de fusión Fc. Reivindicación 13: Una célula huésped que comprende el ácido nucleico de acuerdo con una cualquiera de las reivindicaciones 10 - 12. Reivindicación 41: Un anticuerpo que comprende la proteína Fc no efectora de una cualquiera de las reivindicaciones 1 - 9.
ARP210102188A 2020-08-07 2021-08-05 Proteínas de fusión del ligando para flt3 y métodos de uso AR123158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063062713P 2020-08-07 2020-08-07

Publications (1)

Publication Number Publication Date
AR123158A1 true AR123158A1 (es) 2022-11-02

Family

ID=77519822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102188A AR123158A1 (es) 2020-08-07 2021-08-05 Proteínas de fusión del ligando para flt3 y métodos de uso

Country Status (18)

Country Link
US (2) US11542308B2 (es)
EP (1) EP4192854A1 (es)
JP (1) JP2023536655A (es)
KR (1) KR20230042596A (es)
CN (1) CN116234830A (es)
AR (1) AR123158A1 (es)
AU (1) AU2021322239A1 (es)
BR (1) BR112023002123A2 (es)
CA (1) CA3188426A1 (es)
CL (1) CL2023000381A1 (es)
CO (1) CO2023001488A2 (es)
CR (1) CR20230119A (es)
IL (1) IL300260A (es)
MX (2) MX2023001441A (es)
PE (1) PE20230983A1 (es)
TW (1) TW202221016A (es)
WO (1) WO2022031876A1 (es)
ZA (1) ZA202300862B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123158A1 (es) * 2020-08-07 2022-11-02 Genentech Inc Proteínas de fusión del ligando para flt3 y métodos de uso
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2023235886A2 (en) * 2022-06-03 2023-12-07 The University Of Chicago Antigen tolerance induction through use of flt3l variants

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US7294331B2 (en) 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
ATE473015T1 (de) 2001-10-25 2010-07-15 Government Of The Us Secretary Effiziente hemmung des eintritts von hiv-1-virus durch ein neues fusionsprotein mit cd4
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003224810B2 (en) * 2002-03-26 2006-08-31 Immunex Corporation Methods of using Flt3-ligand in immunization protocols
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050232931A1 (en) 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US20090311247A1 (en) 2005-01-25 2009-12-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
MY162489A (en) * 2010-12-23 2017-06-15 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY Fc MUTANTS
GB201107170D0 (en) 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition
US10160793B2 (en) 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
US11369663B2 (en) * 2016-06-07 2022-06-28 Washington University Detection of CD5 and methods and compositions for modulating CD5
WO2018013818A2 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
UA128669C2 (uk) * 2016-10-14 2024-09-25 Ксенкор, Інк. ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
US11246908B2 (en) 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
WO2019178101A1 (en) * 2018-03-13 2019-09-19 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
US10780121B2 (en) * 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
AU2019349874A1 (en) * 2018-09-28 2021-04-29 Lyvgen Biopharma Holdings Limited Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
WO2020069382A1 (en) 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
CN113645987A (zh) * 2019-03-28 2021-11-12 奥里尼斯生物科学股份有限公司 针对fms样酪氨酸激酶3(flt3)的嵌合蛋白和嵌合蛋白复合物
CR20210687A (es) * 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
MX2023000888A (es) * 2020-07-21 2023-02-22 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
AR123158A1 (es) * 2020-08-07 2022-11-02 Genentech Inc Proteínas de fusión del ligando para flt3 y métodos de uso

Also Published As

Publication number Publication date
CA3188426A1 (en) 2022-02-10
JP2023536655A (ja) 2023-08-28
ZA202300862B (en) 2025-05-28
BR112023002123A2 (pt) 2023-03-07
MX2023001440A (es) 2023-03-06
AU2021322239A1 (en) 2023-02-23
WO2022031876A1 (en) 2022-02-10
US20220289803A1 (en) 2022-09-15
PE20230983A1 (es) 2023-06-21
KR20230042596A (ko) 2023-03-28
US11542308B2 (en) 2023-01-03
CR20230119A (es) 2023-05-16
TW202221016A (zh) 2022-06-01
MX2023001441A (es) 2023-03-06
CN116234830A (zh) 2023-06-06
CL2023000381A1 (es) 2023-07-28
EP4192854A1 (en) 2023-06-14
IL300260A (en) 2023-03-01
US20230279067A1 (en) 2023-09-07
CO2023001488A2 (es) 2023-02-16

Similar Documents

Publication Publication Date Title
AR123158A1 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
ATE68014T1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
ES8802394A1 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
ATE546533T1 (de) Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form
PE20230486A1 (es) Polipeptidos y sus usos
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
ES2114539T3 (es) Expresion de polipeptidos recombinados con purificacion mejorada.
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
WO2021198706A3 (en) Coronavirus vaccines
AR067658A2 (es) Un polipeptido inmunogenico, un polinucleotido que lo codifica , las composiciones farmaceuticas que contienen dichos polipeptidos y polinucleotido, los vectores de xpresion, vacunas, un metodo para la preparacion de dicho polipeptido y una celula huesped aislada que expresa dicho polipeptido
AR065074A1 (es) Peptidos de senalizacion
MX2023008351A (es) Heterodimeros de proteinas de membrana tipo i y metodos de uso de los mismos.
YU218690A (sh) Postupak za pripremanje protein kompleksa u kojima deluje faktor viii:c
AR013190A1 (es) Semaforina l humana (h-sema-l) que contiene un dominio de sema caracteristico, un acido nucleico que la codifica, procedimiento para lapreparacion de semaforinas, utilizacion de la semaforina tipo l y utilizacion de la secuencia de acido nucleico para la fabricacion de un medicamento,
JP2020529221A5 (es)
PE20231442A1 (es) Proteinas actrii y sus usos
ATE378590T1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
MX2023014118A (es) Proteina de fusion de anticuerpo con dominio del ligando de nkg2d.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
ES2254043T1 (es) Proteinas fluorescentes y cromoproteinas procedentes de especies hidrozoa que no son aequorea y metodos para usarlas.
WO2023038961A3 (en) Common cold coronavirus t cell epitopes, methods and uses thereof
PE20251064A1 (es) Acido nucleico aislado que codifica una proteina de fusion basada en fviii-bdd y en un peptido senal heterologo, y uso de la misma
AR123961A1 (es) Composiciones y métodos para el tratamiento de la celiaquía